ω-3酸乙酯(Trygg Pharma AS)(Omega-3-acid ethyl esters(Trygg Pharma AS)) - 药物靶点：Lipid x Triglyceride_在研适应症：高脂血症，高甘油三酯血症，心血管疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Lotriga Granular、Omega-3 fatty acid ethyl esters、OMEGA-3-ACID ETHYL ESTERS

+ [18]

靶点

Lipid x Triglyceride

作用机制

脂质调节剂、甘油三酯调节剂

治疗领域

内分泌与代谢疾病肿瘤心血管疾病

在研适应症

高脂血症高甘油三酯血症心血管疾病+ [1]

非在研适应症

颈动脉狭窄IV型高脂蛋白血症

原研机构

Trygg Pharma AS

在研机构

BASF Corp.Pronova BioPharma ASA

Takeda Pharmaceutical Co., Ltd.

+ [1]

非在研机构

雅培贸易（上海）有限公司AbbVie Pharmaceuticals GmbH

江苏恒瑞医药股份有限公司

+ [5]

最高研发阶段批准上市

首次获批日期

美国 (2004-11-10),

高甘油三酯血症

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构

分子式C46H70O4

InChIKeyDTMGIJFHGGCSLO-FIAQIACWSA-N

CAS号861006-80-6

关联

373

项与 ω-3酸乙酯(Trygg Pharma AS) 相关的临床试验

ChiCTR2400084087 / Suspended临床1期IIT

Pre IVF/ICSI intake Omega 3 Fatty Acid in PCOS patients:A multicenter, randomized, double-blind, placebo-controlled clinical trial

开始日期2025-06-01

申办/合作机构-

NCT06434948 / Not yet recruiting临床2期IIT

The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery: a Prospective, Randomized, Controlled Trial

The purpose of this study is to determine whether giving omega-3 fatty acids prior to and after cardiac bypass surgeries decreases the incidence of postoperative delirium in patients aged 65 and over.

开始日期2024-11-01

申办/合作机构

University of Missouri

CTRI/2024/10/074974 / Not yet recruitingN/AIIT

Effect Of Omega 3 Fatty Acid and Low Dose Aspirin as An Adjunct to Periodontal Therapy in Chronic Periodontitis Patients with Type II Diabetes - NIL

开始日期2024-10-15

申办/合作机构-

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的临床结果

登录后查看更多信息

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的转化医学

登录后查看更多信息

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的专利（医药）

登录后查看更多信息

457

项与 ω-3酸乙酯(Trygg Pharma AS) 相关的文献（医药）

2024-11-01·Journal of Atherosclerosis and Thrombosis

Comparison of Efficacy between Pemafibrate and Omega-3-Acid Ethyl Ester in the Liver: the PORTRAIT Study

Article

作者: Sumida, Yoshio ; Sakamoto, Kazumasa ; Yoneda, Masashi ; Ito, Kiyoaki ; Kimoto, Satoshi ; Toyoda, Hidenori ; Yasuda, Satoshi ; Osonoi, Takeshi ; Nakade, Yukiomi

AIM:

No pharmacotherapeutic treatment has been established for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). This trial compared the effects of pemafibrate and omega-3-acid ethyl ester on hepatic function in patients with hypertriglyceridemia complicated by MASLD.

METHODS:

Patients with hypertriglyceridemia complicated by MASLD were enrolled, randomly assigned to the pemafibrate or omega-3-acid ethyl ester group, and followed for 24 weeks. The primary endpoint was the change in alanine aminotransferase (ALT) from baseline to week 24. The secondary endpoints included other hepatic enzymes, lipid profiles, and hepatic fibrosis biomarkers.

RESULTS:

A total of 80 patients were enrolled and randomized. The adjusted mean change in ALT from baseline to week 24 was significantly lower in the pemafibrate group (-19.7±5.9 U/L) than in the omega-3-acid ethyl ester group (6.8±5.5 U/L) (intergroup difference, -26.5 U/L; 95% confidence interval, -42.3 to -10.7 U/L; p=0.001). Pemafibrate significantly improved the levels of other hepatic enzymes (aspartate aminotransferase and gamma-glutamyl transpeptidase), lipid profiles (triglycerides, total cholesterol, high-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol), and hepatic fibrosis biomarkers (Mac-2 binding protein glycan isomer and Fibrosis-4 index). No cases of discontinuation due to adverse drug reactions were identified in either group, and there were no safety concerns.

CONCLUSIONS:

Pemafibrate is recommended over omega-3-acid ethyl ester for lipid management and MASLD treatment in patients with hypertriglyceridemia complicated by MASLD. The study results may contribute to the development of future treatment strategies for patients with MASLD/MASH.

2024-09-01·LIPIDS

Efficacy and safety of omega‐3‐acid ethyl acetate 90 capsules in severe hypertriglyceridemia: A randomized, controlled, multicenter study

Article

作者: Dai, Hailong ; Li, Jin ; Yao, Zhuhua ; Zhao, Wang ; Chen, Tao ; Wang, Yangang ; Yin, Delu ; Zhao, Shuiping

Abstract:

Omega‐3‐acid ethyl acetate 90 capsules (containing 465 mg of eicosapentaenoic acid and 375 mg docosahexaenoic acid) is composed of highly purified omega‐3 polyunsaturated fatty acid (PUFA) ethyl esters, whose lipid‐lowering effect for severe hypertriglyceridemia (HTG) treatment is unclear. This study aimed to evaluate the efficacy and safety of omega‐3‐acid ethyl acetate 90 capsules in patients with severe HTG. In this randomized, double‐blind, placebo‐controlled, multicenter study, 239 patients with severe HTG were enrolled and randomized (1:1) into omega‐3 group (N = 122) and placebo group (N = 117) to receive 12‐week corresponding treatments. Lipid‐related indexes were obtained at treatment initiation (W0), 4 weeks (W4), W8, and W12 after treatment. Adverse events and adverse drug reactions were recorded. Triacylglycerols (TAG), total cholesterol (TC), non‐high‐density lipoprotein cholesterol (non‐HDL‐C), very‐low‐density lipoprotein cholesterol (VLDL‐C), and apolipoprotein C‐III (Apo C‐III) at W4, W8, and W12 were decreased in the omega‐3 group versus the placebo group (all p < 0.05). Moreover, the percentage changes of TAG, TC, non‐HDL‐C, and VLDL‐C from W0 to W4, W8, and W12, and the percentage change of Apo C‐III from W0 to W4 and W8, were more obvious in the omega‐3 group compared with the placebo group (all p < 0.05). However, no difference was observed in the percentage changes of HDL‐C, low‐density lipoprotein cholesterol (LDL‐C), and LDL‐C/HDL‐C ratio during follow‐up between groups (all p > 0.05). Additionally, there was no discrepancy in adverse events and adverse drug reactions between groups (all p > 0.05). Omega‐3‐acid ethyl acetate 90 capsules exhibit satisfied lipid‐lowering effect with tolerable safety profile in patients with severe HTG.

2024-08-01·Cardiovascular drugs and therapy

Efficacy and Safety of Omega-3 Fatty Acids in the Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis

Review

作者: Yan, Jie ; An, Fengshuang ; Yang, Danning ; Zhang, Yu ; Liu, Ming

BACKGROUND:

It is widely accepted that omega-3 fatty acids are beneficial in the prevention of cardiovascular disease, but many large randomized controlled trial studies and meta-analyses have come to different conclusions. The evidence for omega-3 fatty acids supplementation to prevent cardiovascular disease remains insufficient. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of several types of omega-3 fatty acids supplements.

METHODS:

We comprehensively searched the online database and found 15 RCTs. The primary efficacy outcomes included major cardiovascular events, myocardial infarction, heart failure, atrial fibrillation, stroke, cardiovascular death, and all-cause death. The safety endpoints included gastrointestinal problems, bleeding-related disorders, and cancer. Subgroup analysis was conducted according to the main characteristics of the population, and the dose-response relationship of omega-3 fatty acids was evaluated by meta-regression. All results were calculated by the random effect model. Statistical heterogeneity was assessed using chi-square tests and quantified using I-square statistics.

RESULTS:

The incidence of major cardiovascular events (RR 0.95, 95%CI 0.91 to 0.99, P = 0.026), myocardial infarction (RR 0.90, 95%CI 0.83 to 0.98; P = 0.021), and cardiovascular death (RR 0.94, 95%CI 0.88 to 0.99; P = 0.028) was reduced in the omega-3 fatty acid group compared with the control group. An increased risk of atrial fibrillation (RR 1.25, 95%CI 1.10 to 1.41; P = 0.000) was observed in patients in the omega-3 fatty acid group. No statistical differences were observed between the two groups in heart failure, stroke, and all-cause death. For safety endpoints, there were no statistically significant differences between the two groups in gastrointestinal problems, bleeding-related disorders, and cancer. Subgroup analysis showed that the cardiovascular benefit of omega-3 fatty acids was primarily attributable to the prescription of EPA ethyl ester. Omega-3 fatty acids may reduce the risk of major cardiovascular events in patients with cardiovascular disease or risk factors, and reduce the risk of myocardial infarction in patients without cardiovascular disease; however, they may increase the risk of stroke in patients with myocardial infarction. In addition, prescription omega-3 acid ethyl ester has a good safety profile, and prescription EPA ethyl ester has a high risk of bleeding.

CONCLUSION:

Moderate evidence showed that the use of omega-3 fatty acids may reduce the risk of major cardiovascular events, myocardial infarction, and cardiovascular death. Compared to other types of omega-3 fatty acids supplements, we support the use of prescription EPA ethyl ester formulations for the prevention of cardiovascular disease, but the potential risk of atrial fibrillation and bleeding cannot be ignored. It is important to note that omega-3 fatty acids should be applied with caution in patients with previous myocardial infarction, which may increase the risk of stroke. Finally, omega-3 fatty acids are relatively safe and in general do not increase gastrointestinal problems, bleeding-related disorders, or cancer, but attention needs to be paid to the risk of bleeding with prescription EPA ethyl ester formulations.

28

项与 ω-3酸乙酯(Trygg Pharma AS) 相关的新闻（医药）

2024-10-22

·派真生物PackGene

基因疗法在体内自动将Omega-6转化为Omega-3脂肪酸

根据美国疾病控制中心的数据，近20%的儿童和青少年被认为是肥胖的。研究表明，肥胖可能会对多种健康状况产生显著影响，包括关节炎、心脏疾病和其他代谢问题，美国儿科学会现在推荐早期和强化治疗来对抗肥胖。在过去的四年里，圣路易斯的Shriners儿童医院的研究人员一直在开发一种新的方法来预防儿童肥胖的影响。 Shriners儿童医院圣路易斯研究主任Farshid Guilak博士和资深科学家Ruhang Tang博士发现了一种革命性的新方法-基因疗法，将有害的脂肪酸转化为有益的脂肪酸，使肥胖儿童能够降低其他健康问题的风险，特别是关节炎。 “我们已经知道，儿童患关节炎的头号可预防风险因素是超重，” Guilak博士说。“我们的典型反应只是告诉孩子们减肥，而没有解决更大的问题。儿童肥胖已经成为一种流行病，结果，关节炎在儿童中变得越来越普遍。我们的一个关键发现是，不仅仅是肥胖本身有害，饮食也是如此。儿童摄入的脂肪酸类型在儿童体重增加中起着重要作用。一旦儿童变得肥胖，它就为其他重大健康问题打开了大门，这些健康问题很难逆转。” Tang博士说，他们的基因疗法技术涉及使用腺相关病毒（AAV），一种不能复制的病毒，将特定酶的基因递送到细胞中。新的基因疗法自动将高度炎症的Omega-6脂肪酸转化为对身体代谢健康更有利的Omega-3脂肪酸。Guilak博士说，来自脂肪食品和植物油（如油炸食品）的Omega-6酸倾向于促进炎症，并可能导致关节炎、心脏病和代谢问题等健康问题。在鱼类和某些坚果中发现的Omega-3可以通过改善胰岛素敏感性、促进脂肪代谢和减少炎症以及降低肥胖相关疾病的风险来支持更健康的代谢概况。研究的共同领导者Natalia Harasymowicz博士说，他们的基因疗法还能够减少在促进与肥胖相关的炎症和关节炎中至关重要的促炎细胞的数量。在这项研究中，研究人员研究了一种在儿童中非常常见的关节炎类型，称为“创伤后关节炎”，由膝关节受伤引起，如作为稳定器和缓冲器的半月板组织的撕裂。团队发现，一次性的基因疗法显著减少了高脂肪、富含Omega-6的饮食对整体代谢健康和膝关节炎的影响（图1）。特别有趣的发现是，饮食诱导的肥胖导致这些小鼠过早“衰老”，这被基因疗法阻止了。图1 高脂饮食（HFD）28周和52周后的系统性肥胖特征和内侧半月板不稳定（DMM） “我们观察到的是，肥胖导致年轻患者的膝盖老化，” Guilak博士说。“现代饮食，特别是在美国，往往Omega-6含量高，Omega-3含量低，这可能导致不平衡，尤其是对孩子们来说。我们开发的基因疗法将自动在体内将Omega-6转化为Omega-3脂肪酸，有效地将坏脂肪变成好脂肪。关节炎对儿童来说可能是一种非常痛苦和致残的疾病，所以我们希望这项研究有助于降低它发展的风险，并使治疗更加有效。这项研究未来可能如何被使用的影响是巨大的，但我们对它帮助孩子们过上更健康的生活感到兴奋。” Guilak博士也是圣路易斯华盛顿大学骨科手术的Mildred B. Simon教授，以及华盛顿大学再生医学中心的联合主任。他的团队正在与食品药品监督管理局（FDA）合作，计划在未来3-5年内进入临床试验。 Shriners儿童医院的研究团队开发革命性的新方法-基因疗法，将有害脂肪酸转化为有益脂肪酸，有效降低肥胖儿童患关节炎等健康问题的风险，对于提升儿童的身心健康、降低医疗负担以及推动社会健康进步都具有重要意义。派真CRO & CDMO一站式服务平台，提供从基因合成、载体构建，到病毒包装的整体解决方案，可全面支持肥胖疾病基因编辑研究。我们还提供多种AAV现货产品，欢迎后台留言咨询。资料来源: https://www.prnewswire.com/news-releases/shriners-childrens-st-louis-develops-new-technology-to-prevent-childhood-obesity-302278182.html 关于派真生物

基因疗法临床研究

2024-08-02

·drugs

Fish Oil Might Help High-Risk Older Adults Avoid Alzheimer's

FRIDAY, Aug. 2, 2024 -- Fish oil supplements might help high-risk seniors stave off Alzheimer’s disease, a new study finds. Older people with a higher genetic risk of Alzheimer’s experienced slower breakdown of their brain’s nerve cells if they took fish oil capsules, researchers reported Aug. 1 in the journal JAMA Network Open . These people carry the APOE4 gene variant, which increases risk of Alzheimer’s and is associated with an earlier age of onset, according to the National Institute on Aging. “The fact that neuronal integrity breakdown was slowed in people randomized to omega-3 treatment who are also at high risk for Alzheimer’s disease is remarkable, and warrants a larger clinical trial in more diverse populations in the future,” said researcher Gene Bowman , a neurology instructor with the McCance Center for Brain Health at Massachusetts General Hospital in Boston. However, fish oil supplements did not benefit all seniors in general, researchers noted. “Our findings showed that over three years, there was not a statistically significant difference between placebo and the group that took fish oil,” said researcher Dr. Lynne Shinto , a professor of neurology with the Oregon Health & Science University School of Medicine. “I don’t think it would be harmful, but I wouldn’t say you need to take fish oil to prevent dementia.” For the study, researchers recruited 102 people ages 75 and older who had relatively low levels of omega-3 fatty acids, the beneficial ingredient in fish oil. Fish oil supplements are touted as a means of improving brain function in people with memory problems, researchers said in background notes. Participants received MRI brain scans at the start of the study and after three years looking for white matter lesions in the brain. All had relatively high levels of white matter lesions but were otherwise healthy, with no dementia. These lesions can inhibit the ability of blood vessels to feed brain cells, increasing a person’s future risk of dementia, researchers said. Half the participants were asked to take daily fish oil supplements, and the other half took a soybean-based placebo. The MRI scans found a slight reduction in the progression of white matter lesions among people who took fish oil, but not enough to be statistically significant, researchers said. However, APOE4 carriers who took fish oil experienced a dramatic reduction in the breakdown of their brain cell integrity as soon as one year after starting on fish oil, compared to the placebo group. “This is the first dementia prevention trial to use modern prevention tools, such as a blood test and brain scan, to identify not only people at high risk for dementia, but also those well-suited to receive a specific nutritional intervention,” Bowman said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

2024-07-11

·药融圈

投资9.8亿！浙江海之心年产5350吨高纯度心血管原料药及13亿粒制剂项目（EPA&DHA）

▲8月15-16日 NDC2024生物医药创新者峰会扫码报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。【原料药情报局】获悉：近日，关于浙江海之心制药有限公司年产5350吨高纯度心血管原料药95/98.13亿粒制剂建设项目在相关网站审批公示。项目基本情况项目名称：浙江海之心制药有限公司年产5350吨高纯度心血管原料药95/98.13亿粒制剂建设项目建设性质：新建建设单位：浙江海之心制药有限公司建设单位母公司：俊达集团&江苏海莱康生物科技有限公司建设地点：仙居县福应街道经济开发区现代工业集聚区春晖中路南侧建设周期：2024年7月至2026年7月建设内容及规模：项目总投资98000万元，总用地面积59931.00m2，总建筑面积59204.35m2，建设生产车间6幢，动力车间1幢，仓库5幢，罐区设置储罐10个（并预留10个），生产EPA70EE 3496t/a、EPA98 997.484t/a、DHA95 349.95t/a，EPA98制剂10亿粒/年，DHA95制剂3亿粒/年，产生副产品低沸鱼油3354.99t/a、食品鱼油（含DHA70EE）2534.60t/a、氯化银5.066t/a。 EPA最早于2012年被美国FDA批准上市，用于降低严重高甘油三酯血症（TG≥500mg/dl）成人患者的甘油三脂水平，是FDA批准的首个纯EPA处方药。2019年12月二十碳五烯酸乙酯（商品名：Vacsepa）获FDA批准，成为首个辅助他汀类降低高危患者心血管风险的药。高纯度EPA和DHA凭借其保健功能和对心血管疾病的治疗和预防功能，被广泛应用于饲料添加剂、保健品和药品等产品中。江苏海莱康生物科技有限公司是一家专注于高含量EPA/DHA产品研发、生产和销售的高科技企业，成立于2020年9月，坐落于江苏省苏州市昆山市。自2010年开始将深海提炼物进行深加工研究，在EPA（二十碳五烯酸乙酯）和DHA（二十二碳六烯酸乙酯）提纯领域已取得重大技术突破，EPA纯度可达98%以上，DHA纯度可达95%以上。拥有规模化生产高纯度DHA/EPA的先进生产技术，年生产能力3200吨。关于二十碳五烯酸乙酯二十碳五烯酸乙酯，也称为EPA乙酯,是一种Omega-3脂肪酸衍生物,其来源于二十碳五烯酸(EPA)。它在抗炎、心脑血管保健及促进心理健康等方面展示了广泛的应用价值。EPA-EE通过抑制炎症介质的产生、改善血脂谱、稳定斑块等多种机制发挥作用。自1990年以来，EPA-EE在全球范围内逐渐受到认可，并在2012年由Amarin公司的Vascepa（商品名）在美国FDA获得批准，作为降低动脉粥样硬化性疾病风险的处方药物。 2023年，中国市场也先后批准了两款基于二十碳五烯酸乙酯（IPE）的药物。2月，国为医药的"立瑞欣®"获批用于降低重度高甘油三酯血症患者的甘油三酯水平；6月，亿腾医药"唯思沛"获批上市，用以减少已通过他汀类药物治疗的患者的心血管事件风险。此外，诚意药业正推进1000吨EPA原料药产能的建设，仁普药业与新华制药达成战略合作，每年可向全球API客户提供数百吨的Omega-3原料药。 CDE原料药登记版权声明：本文转自原料药情报局，如不希望被转载的媒体或个人可与我们联系，我们将立即删除 8月15日 C馆C105 创新药中美双报如何制定研发策略策划人：邹灵龙康维讯生物，创始人、董事长&CEO 会议日程 09:00-09:30 TBD 曹国帅 | 天港医诺，研发负责人 09:30-10:00 抗体药物中美IND快速申报策略姜伟东 | 康抗生物，创始人&CEO 10:00-10:30 中美IND申请非临床研究要点贺全仁 | 艾博生物，药理毒理高级副总裁 10:30-11:00 中美申报CMC要点 Audrey Jia | 前FDA药学审评员、Data Revive创始人 11:00-11:30 中美双报生物分析策略与实操分享邹灵龙 | 康维讯生物，创始人、董事长&CEO 11:30-12:00 创新药中美双报项目进展分享嘉宾行程确认中 12:00-13:30 午餐 13:30-14:00 Immunogenicity Testing Strategy & Regulatory Expectation on Method Validation- FDA perspective 严皓珩 | 复宏汉霖，美国注册负责人，前FDA评审 14:00-14:30 出海申报的临床试验设计与数据管理杨修诰 | 石药集团，高级医学总监 14:30-15:00 支持出海的ADC毒素ADME研究朱明社 | 锐迪欧医药，首席科学官&首席顾问 15:00-15:30 中美药品电子申报 (eCTD)要点任翀 | 复宏汉霖，药政注册副总监 15:30-16:30 圆桌对话：创新药中美双报路径，如何从多维度评估价值回报? 1.创新药在中美两国市场准入策略？ 2.市场准入路径对药品价值的影响 3.进行临床试验时应考虑哪些关键因素？ 4.监管合规性对药品上市时间和成本的影响？ 5.如何识别和管理潜在风险？陈春麟 | 美迪西生物，创始人&CEO （更多嘉宾行程确定中）扫码报名参会【关于药融圈】药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等多个领域，服务了百余家上市/独角兽/生物技术/制药企业。

上市批准医药出海

100 项与 ω-3酸乙酯(Trygg Pharma AS) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05255	ω-3酸乙酯(Trygg Pharma AS)	C10AX06	DB09539

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高脂血症	日本	Takeda Pharmaceutical Co., Ltd.	2012-09-28
高甘油三酯血症	美国	Woodward Pharma Services LLC初创企业	2004-11-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
IV型高脂蛋白血症	临床3期	中国	Pronova Biopharma Norge AS	2016-09-19
IV型高脂蛋白血症	临床3期	中国	AbbVie Pharmaceuticals GmbH	2016-09-19
IV型高脂蛋白血症	临床3期	中国	雅培贸易（上海）有限公司	2016-09-19
IV型高脂蛋白血症	临床3期	中国	GMPack ApS	2016-09-19
心血管疾病	临床3期	美国	BASF Corp.	2010-07-01
心血管疾病	临床3期	美国	Pronova BioPharma ASA	2010-07-01
肿瘤	临床3期	美国	Pronova BioPharma ASA	2010-07-01
肿瘤	临床3期	美国	BASF Corp.	2010-07-01
颈动脉狭窄	临床3期	英国	Pronova BioPharma ASA	2003-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04181593 (CTgov)	临床3期	干眼综合征	322	Omega 3 fatty acid (OmegaD)	網網餘齋膚衊廠遞範願(鹹築顧鏇淵壓衊繭鑰鑰) = 範簾膚壓鹽觸積選遞膚醖願範顧觸簾遞憲鹹鏇 (窪餘構築膚鏇淵糧鏇壓, 齋鬱願艱鏇遞範膚築觸 ~ 鬱窪夢範鏇繭獵窪鬱觸) 更多	-	2024-07-29
				Placebos (Placebo)	網網餘齋膚衊廠遞範願(鹹築顧鏇淵壓衊繭鑰鑰) = 製構遞鹽選鏇築廠淵餘醖願範顧觸簾遞憲鹹鏇 (窪餘構築膚鏇淵糧鏇壓, 選願齋蓋襯夢簾範鑰淵 ~ 壓築窪願廠繭繭糧簾膚) 更多
NCT03387098 (P713, CTgov)	临床1/2期	胰腺癌	4	SBRT+Aldoxorubicin HCl+GI-4000+lovaza+ETBX-011+fluorouracil+ALT-803+Nab-paclitaxel+Cyclophosphamide+Avelumab+haNK for infusion+Leucovorin+Bevacizumab+Oxaliplatin+Capecitabine	鏇夢鹽網蓋艱遞淵觸蓋(製鹹觸夢窪襯簾襯窪積) = 選膚顧願憲選鹹積築積齋糧艱觸襯壓憲鹽鬱鏇 (選夢糧願顧觸獵夢夢簾, 範鬱艱鏇廠觸顧齋鏇積 ~ 鹹簾遞鑰遞積範夢齋遞) 更多	-	2024-05-22
NCT00746811 (CTgov)	临床4期	原发性高胆固醇血症	32	P-OM3 (P-OM3)	襯淵鏇遞積製築顧鏇鑰(衊積鑰構糧繭繭窪遞艱) = 衊築積膚鹽繭衊憲餘繭窪築簾製齋鬱選壓鏇積 (壓遞鹹築襯鏇鑰網築窪, 膚餘範壓襯衊醖簾繭醖 ~ 選憲窪製憲襯蓋窪鹹齋) 更多	-	2024-05-08
				Placebo (Placebo)	襯淵鏇遞積製築顧鏇鑰(衊積鑰構糧繭繭窪遞艱) = 鑰選構鹽齋構顧願糧襯窪築簾製齋鬱選壓鏇積 (壓遞鹹築襯鏇鑰網築窪, 鏇窪願構遞積積顧網鏇 ~ 襯蓋廠積鬱繭遞獵蓋願) 更多
AASLD2023	N/A	-	-	Fenofibrate	鬱製憲鹽築艱壓憲網遞(壓積鏇繭憲選願範積製) = 構願淵鹽鏇鏇範壓構願餘選蓋獵淵夢選蓋衊齋 (鏇襯糧壓觸獵範範糧醖 ) 更多	-	2023-11-10
				Bezafibrate	鬱製憲鹽築艱壓憲網遞(壓積鏇繭憲選願範積製) = 製衊遞積憲製餘膚鏇範餘選蓋獵淵夢選蓋衊齋 (鏇襯糧壓觸獵範範糧醖 ) 更多
NCT04198805 (PUVENAFLD, CTgov)	临床2期	胰岛素抵抗 \| 非酒精性脂肪性肝炎 \| 高血压	205	Omega-3 fatty acid+Vitamin E (DHA EE (1.89 g) and Vitamin E (1000 mg))	鏇襯鏇餘繭製廠艱壓製(製製憲築襯築憲夢築願) = 範醖蓋醖醖廠網構糧繭顧簾鬱艱鹽廠餘淵製夢 (鬱憲鹹醖鹽糧蓋蓋簾網, 廠觸範蓋築簾襯窪壓構 ~ 齋網繭築壓蓋簾鑰膚範) 更多	-	2023-05-25
				Placebo (Placebo)	鏇襯鏇餘繭製廠艱壓製(製製憲築襯築憲夢築願) = 獵襯鏇觸鬱構積範憲簾顧簾鬱艱鹽廠餘淵製夢 (鬱憲鹹醖鹽糧蓋蓋簾網, 鏇網憲齋鹹夢鬱遞鏇夢 ~ 廠糧鏇積窪遞艱鹽醖繭) 更多
NCT03345550 (OPTIMA, CTgov)	临床2期	脑震荡	44	Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules. (Omega-3 Polyunsaturated Fatty Acid Treatment Arm)	顧網襯範衊遞壓廠醖鹽(遞齋糧憲壓繭膚網鹹糧) = 壓鹹鏇廠餘鏇鑰夢膚選廠鹽簾餘構範鹹淵範鹹 (構積襯膚獵築築鬱簾蓋, 襯鑰顧糧網淵糧淵鹽繭 ~ 襯廠築簾製糧鑰簾願鑰) 更多	-	2023-05-23
				Placebo - Cap (Placebo Arm)	顧網襯範衊遞壓廠醖鹽(遞齋糧憲壓繭膚網鹹糧) = 鏇築製衊繭範廠衊築夢廠鹽簾餘構範鹹淵範鹹 (構積襯膚獵築築鬱簾蓋, 顧鑰選廠積築遞憲廠鬱 ~ 觸鬱壓憲網顧製鬱壓壓) 更多
NCT01669915 (VITAL-Cog, CTgov)	N/A	认知功能障碍	3,424	Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Active Vitamin D)	獵遞糧獵簾膚淵鹽範製(構簾獵簾廠鹽糧餘鹽網) = 遞壓鬱壓獵衊遞餘蓋範淵範鑰衊選齋淵鑰築鏇 (遞膚膚鬱淵鏇廠願範鏇, 艱醖醖簾夢壓繭膚憲醖 ~ 夢壓鹽繭鹽範鬱積鑰鬱) 更多	-	2023-04-21
				Vitamin D (TELEPHONE INTERVIEW ANCILLARY STUDY: Vitamin D Placebo)	獵遞糧獵簾膚淵鹽範製(構簾獵簾廠鹽糧餘鹽網) = 顧顧蓋鹹積鬱繭醖選衊淵範鑰衊選齋淵鑰築鏇 (遞膚膚鬱淵鏇廠願範鏇, 蓋遞網淵築淵艱簾衊積 ~ 鑰鬱範蓋壓製築繭觸範) 更多
NCT01813006 (EUDRACTNR 2012-000505-68, Pubmed)	临床3期	II型高脂蛋白血症	34	Omega-3 polyunsaturated fatty acid supplement	鬱淵窪淵憲鏇簾觸糧窪(窪廠艱鬱遞窪鬱鹹鑰積) = 憲廠衊築築鹹獵窪艱衊構鬱膚襯膚夢艱襯鏇鹹 (夢簾淵網願構繭餘繭齋, [ ~ 13, 6])	-	2023-03-31
NCT01696435 (VITAL \| VITAL-DEP, CTgov)	N/A	抑郁症	18,353	vitamin D3 (Vitamin D + Fish Oil Placebo)	顧壓鏇衊網網鬱窪膚遞(製壓齋構壓鹹壓觸鑰壓) = 鑰範蓋淵齋範獵獵夢築鏇構觸鏇窪範鏇鹹積憲 (鹹鹹壓膚範膚構憲憲鏇, 築積製獵繭窪選遞艱憲 ~ 膚觸簾窪選糧鹹餘壓鹹) 更多	-	2023-03-14
				Vitamin D placebo+omega-3 fatty acids (fish oil) (Vitamin D Placebo + Fish Oil)	顧壓鏇衊網網鬱窪膚遞(製壓齋構壓鹹壓觸鑰壓) = 獵鹹鏇憲遞製構醖築選鏇構觸鏇窪範鏇鹹積憲 (鹹鹹壓膚範膚構憲憲鏇, 齋鹽築蓋獵範餘糧鬱鹽 ~ 構衊壓襯觸廠願壓觸餘) 更多
NCT04495816 (CTgov)	临床2期	新型冠状病毒感染 \| 嗅觉丧失	139	Omega-3 Fatty Acid Supplement (Omega-3)	淵觸鹽獵鬱襯獵鏇簾簾(範夢壓網簾願簾餘壓繭) = 鏇餘蓋選襯鹹廠顧艱蓋蓋製獵築壓獵壓蓋夢壓 (艱鑰繭構鏇齋鹹鬱網積, 簾夢淵鹹築壓鏇壓襯鏇 ~ 鑰襯淵觸蓋壓襯獵遞選) 更多	-	2023-01-31
				Placebo/Control (Placebo/Control)	淵觸鹽獵鬱襯獵鏇簾簾(範夢壓網簾願簾餘壓繭) = 鹹淵衊遞積鬱壓選構憲蓋製獵築壓獵壓蓋夢壓 (艱鑰繭構鏇齋鹹鬱網積, 積夢餘艱觸窪鏇製構醖 ~ 淵齋鬱鹹艱醖構觸餘膚) 更多